Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Lowers Price Target to $50
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and lowers the price target from $51 to $50.
Arcutis’ Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) announced new safety and efficacy durability data from its open-label Phase 2 long-term safety study of roflumilast…
Arcutis Submits Supplemental New Drug Application For ZORYVE Cream 0.3% For Expanded Indication For The Treatment Of Plaque Psoriasis In Children Down To 2 Years Of Age
Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque psoriasis
If
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $51
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $49 to $51.
Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $49
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $46 to $49.
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $46
Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $45 to $46.